These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 12721248)
61. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Anderlini P; Saliba R; Acholonu S; Okoroji GJ; Donato M; Giralt S; Andersson B; Ueno NT; Khouri I; De Lima M; Hosing C; Cohen A; Ippoliti C; Romaguera J; Rodriguez MA; Pro B; Fayad L; Goy A; Younes A; Champlin RE Bone Marrow Transplant; 2005 May; 35(10):943-51. PubMed ID: 15806128 [TBL] [Abstract][Full Text] [Related]
62. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation. Bug G; Atta J; Klein SA; Hertenstein B; Bergmann L; Boehrer S; Mousset S; Hoelzer D; Martin H Ann Hematol; 2005 Oct; 84(11):748-54. PubMed ID: 16001243 [TBL] [Abstract][Full Text] [Related]
63. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786 [TBL] [Abstract][Full Text] [Related]
64. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution. Magagnoli M; Castagna L; Balzarotti M; Sarina B; Timofeeva I; Bertuzzi A; Compasso S; Nozza A; Siracusano L; Santoro A Am J Hematol; 2003 Aug; 73(4):267-72. PubMed ID: 12879431 [TBL] [Abstract][Full Text] [Related]
65. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814 [TBL] [Abstract][Full Text] [Related]
66. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
67. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Schmidt-Hieber M; Blau IW; Trenschel R; Andreesen R; Stuhler G; Einsele H; Kanz L; Keilholz U; Marinets O; Beelen DW; Fauser AA; Volin L; Ruutu T; Uharek L; Fietz T; Knauf W; Hopfenmüller W; Thiel E; Freund M; Casper J Bone Marrow Transplant; 2007 Apr; 39(7):389-96. PubMed ID: 17310135 [TBL] [Abstract][Full Text] [Related]
70. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754 [TBL] [Abstract][Full Text] [Related]
71. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation]. Lin Q; Dong M; Wang QM; Wen JY; Wu XY Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772 [TBL] [Abstract][Full Text] [Related]
72. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436 [TBL] [Abstract][Full Text] [Related]
74. Autologous and allogeneic transplantation for multiple myeloma at a single centre. Couban S; Stewart AK; Loach D; Panzarella T; Meharchand J Bone Marrow Transplant; 1997 Apr; 19(8):783-9. PubMed ID: 9134169 [TBL] [Abstract][Full Text] [Related]
77. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution. Franssen LE; Raymakers RA; Buijs A; Schmitz MF; van Dorp S; Mutis T; Lokhorst HM; van de Donk NW Eur J Haematol; 2016 Nov; 97(5):479-488. PubMed ID: 27028304 [TBL] [Abstract][Full Text] [Related]
78. [Allogeneic bone marrow transplantation for refractory multiple myeloma: presence of a graft-versus-myeloma effect]. Nawa Y; Noguchi T; Kojima K; Hara M Rinsho Ketsueki; 2001 Jun; 42(6):481-7. PubMed ID: 11505527 [TBL] [Abstract][Full Text] [Related]
79. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Worel N; Biener D; Kalhs P; Mitterbauer M; Keil F; Schulenburg A; Höcker P; Dieckmann K; Fischer G; Rosenmayr A; Linkesch W; Hinterberger W; Lechner K; Greinix HT Bone Marrow Transplant; 2002 Nov; 30(9):619-26. PubMed ID: 12407437 [TBL] [Abstract][Full Text] [Related]
80. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]